You are here

Targeting of Myc-Max dimerization for the treatment of cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA189600-01
Agency Tracking Number: R41CA189600
Amount: $224,550.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SAN DIEGO, CA 92121-4746
United States
DUNS: 832545805
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (858) 210-3705
Business Contact
Phone: (858) 210-3701
Research Institution
10550 North Torrey Pines Road
La Jolla, CA 92037-1000
United States

 () -
 Domestic nonprofit research organization

DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of high levels of this oncoprotein. Myc cannot act alone, however, and its oncogenic activity is dependent on heterodimerization with Max. Together, these basic helix-loop-helix leucine zipper (bHLHLZ) proteins interact via a protein-protein interaction (PPI). Notably, a single amino acid substitution within the Myc-Max interaction domain can prevent dimerization. Thus,minor perturbation in the dimer surface can profoundly affect the ability of Myc and Max to interact. This fact strongly supports the idea that it may be possible to identify small molecule inhibitors of the Myc-Max PPI. Sorrento Therapeutics' academ

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government